{
    "Clinical Trial ID": "NCT03366428",
    "Intervention": [
        "INTERVENTION 1: ",
        "  DS-8201a",
        "  Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Has a pathologically documented unresectable or metastatic breast cancer with HER2 expression (immunohistochemistry [IHC] 3+, IHC 2+, IHC 1+ and/or in situ hybridization [ISH] +) that is refractory to or intolerable with standard treatment, or for which no standard treatment is available",
        "  Has a left ventricular ejection fraction (LVEF)  50%",
        "  Has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1",
        "Exclusion Criteria:",
        "  Has a medical history of myocardial infarction within 6 months before enrollment",
        "  Has a medical history of ventricular arrhythmias, other than rare occasional premature ventricular contractions",
        "  Has uncontrolled or significant cardiovascular disease"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Changes in QTcF After Treatment With DS-8201a in Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer",
        "  The number of participants with notable electrocardiogram changes meeting predefined criteria is being reported.",
        "  Time frame: Screening (within 7 days before enrollment) up to Cycle 3 Day 15 (each cycle is 21 days)",
        "Results 1: ",
        "  Arm/Group Title: DS-8201a",
        "  Arm/Group Description: Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle.",
        "  Overall Number of Participants Analyzed: 49",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Maximum change from baseline in QTcF: >30 ms: 3   6.1%",
        "  Maximum change from baseline in QTcF: >60 ms: 0   0.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 9/51 (17.65%)",
        "  Nausea 2/51 (3.92%)",
        "  Cellulitis 1/51 (1.96%)",
        "  Lung infection 1/51 (1.96%)",
        "  Femur fracture 1/51 (1.96%)",
        "  Post procedural complication 1/51 (1.96%)",
        "  Fracture 1/51 (1.96%)",
        "  Interstitial lung disease 1/51 (1.96%)",
        "  Pneumonitis 1/51 (1.96%)"
    ]
}